WASHINGTON, D.C. — Patients reported that a new patient-reported outcome assessment tool developed based on the FDA PRO Guidance for Industry was easy to understand and relevant to their experience of Clostridium difficile-related diarrhea symptoms, according to data presented at ICAAC 2014.